| APCs | Antigen presenting cells |
| BBB | Blood brain barrier |
| CAMs | cell adhesion molecules |
| CNS | Central nervous system |
| ECM | Extracellular matrix |
| EMT | Epithelial–mesenchymal transition |
| EGFR | epidermal growth factors receptor |
| FDA | Food and Drug Administration |
| GAG | Glycosaminoglycans |
| GAM | Glioma-associated macrophage and microglia |
| GASC | Glioma Associated Stem cells |
| GBM | Glioblastoma |
| GCS | Glioma stem cells |
| MET | mesenchymal–epithelial transition |
| PD1 | Programmed cell Death-1 |
| PRISMA-P | Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols |
| SIRT1 | Sirtuin 1 |
| TCR | T cell receptors |
| TGF-β | Transforming growth factor-β |
| TIL | Tumor-infiltrating lymphocytes |
| TME | Tumor Microenvironment |
| TMZ | Temozolomide |